Ipsen has signed an exclusive worldwide collaboration with Skyhawk Therapeutics to discover and develop novel small molecules that modulate RNA for rare neurological diseases.

The agreement includes an option under which Ipsen would acquire an exclusive license for the worldwide rights to develop successful development candidates (DC).

Following the successful DC nomination, Ipsen will be responsible for all activities. Skyhawk's unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases. 

"We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions," said Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen.

"Our focus and expertise in movement disorders, and across our portfolio, is bringing best and first-in-class treatments to those with the highest unmet needs, now further fueled by this novel platform at the cutting-edge of research," said Glyman.

"Ipsen is an extraordinary company with a deep passion for serving patients, and we are excited to partner with them to expand their pipeline of innovative therapies," said Sergey Paushkin, Chief Scientific Officer at Skyhawk.

"Our strategic partnership underscores our shared ambition to develop transformative medicines for people with rare neurological diseases for which there are no approved therapeutics," he added.

Under the terms of the agreement, Skyhawk is eligible to receive up to USD 1.8 billion in development, regulatory and commercial milestones, including an upfront payment, for the option and research collaboration, plus the potential for tiered royalties.